Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

The Medtronic Harmony transcatheter pulmonary valve (TPV) system offers a less invasive treatment option for patients with a congenital heart defect irregularity in their right ventricular outflow tract (RVOT) that requires a pulmonary valve placement to restore valve function. 
Feature | Structural Heart | Dave Fornell, Editor
One-year Results of the Harmony Transcatheter Pulmonary Valve Trial Presented at SCAI 2021 

April 30, 2021 — New study results validate the effectiveness of the Medtronic Harmony transcatheter pulmonary valve ...

Home April 30, 2021
Home
The two FDA-clear transcatheter aortic valve replacement (TAVR) valves on the market, the Edwards Lifesciences Sapien 3 (left) and the Medtronic CoreValve (right).
Feature | Structural Heart
TAVR Access is Inequitable Based Socioeconomics Level and Geography

April 30, 2021 – An analysis of growth patterns in transcatheter aortic valve replacement (TAVR) programs across United ...

Home April 30, 2021
Home
New study demonstrates depression, HIV, mental health, obesity, alcohol and drug abuse are risk factors on most common type of heart disease in young black patients. Photo by Dave Fornell
News | Cath Lab
Young African Americans With Coronary Disease Impacted by Non-traditional Risk Factors

April 29, 2021 – A retrospective analysis of risk factors for coronary artery disease (CAD) in young African American ...

Home April 29, 2021
Home
The Abiomed Impella percutaneous heart pump was shown in the NCSI study to greatly improve survival of acute myocardial infarction with cardiogenic shock (AMICS), raising survival from 50 percent to 71 percent. Ambulance image from Getty Images.
Feature | Cardiogenic Shock | By Dave Fornell, Editor
National Cardiogenic Shock Initiative Protocol Shows 71 Percent Survival 

April 29, 2021 — The results of a large, national heart attack study show that patients with  cardiogenic shock survived ...

Home April 29, 2021
Home
A Chinese registry study found there are higher event rates in patients with shorter dual-antiplatelet therapy (DAPT) after PCI procedures. There has been a lot of movement toward using shorter duration DAPT with newer generation drug-eluting stent technologies, but this study reinforces the need longer DAPT in many patients. The findings were presented as a late-breaking trial at SCAI 2021 today. 
News | Antiplatelet and Anticoagulation Therapies
Long-term Dual Antiplatelet Therapy Benefits Reinforced in SCAI Late-breaking Study

April 28, 2021 — An analysis of the prospective Chinese Fuwai PCI Registry, confirms long-term, dual-antiplatelet ...

Home April 28, 2021
Home
The STAT2 trial used a combination of the Biolife Statseal potassium ferrate hemostatic patch and a Terumo TR Band to reduce radial access arteriotomy site hemostasis by 50 percent.
News | Radial Access | Dave Fornell, Editor
Radial Hemostasis Time Cut by 50 Percent With StatSeal in Combination With TR Band

April 28, 2021 — A new study reveals the use of a potassium ferrate hemostatic patch (PFHP) reduces the time to ...

Home April 28, 2021
Home
Videos | Cardiogenic Shock
VIDEO: Final Results of the National Cardiogenic Shock Initiative Show 71 Percent Survival

William O’Neill, M.D., medical director of the Center for Structural Heart Disease at Henry Ford Hospital, Detroit ...

Home April 28, 2021
Home
There are far fewer patients coming to hospitals with heart attacks during the COVID-19 pandemic as compared to averages prior to the pandemic. This has raised concerns that delayed treatment will cause an uptick in cardiac deaths and heart failure. Photo from Getty Images 
News | Cath Lab
COVID Caused Major Decline in Heart Attack Patients Seeking Care

April 28, 2021 – Results from a retrospective observational study, presented today at Society for Cardiovascular ...

Home April 28, 2021
Home
A cardiac cath lab at Henry Ford Hospital in Detroit. Photo by Dave Fornell
News | Cath Lab
SCAI Updates Best Practices in the Cardiac Cath Lab Guidelines Document

April 28, 2021 — The Society for Cardiovascular Angiography and Interventions (SCAI) has released an expert consensus ...

Home April 28, 2021
Home
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a structural heart procedure at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell
Feature | Structural Heart
Advice For Hospitals Starting a Structural Heart Program

The resounding success of transcatheter aortic valve replacement (TAVR) has led the creation of hundreds of structural ...

Home April 22, 2021
Home
The FDA’s market clearance occurred once the agency reviewed EnsiteVascular’s Section 510(k) premarket notification of intent to market the SiteSeal SV device and determined it is substantially equivalent for the indication for use stated: brachial artery closure. Previously, EnsiteVascular received FDA market clearance for SiteSeal SV for radial artery closure.
News | Hemostasis Management
FDA Clears SiteSeal SV Vascular Closure Device for the Brachial Arteries

April 21, 2021 — EnsiteVascular announced it received its second U.S. Food and Drug Administration (FDA) market ...

Home April 21, 2021
Home
Transesophageal echo (TEE) being used to guide the deployment of a MitraClip device during a transcatheter structural heart procedure in the hybrid lab at the University of Colorado Hospital. The center has performed more than 200 MitraClip mitral valve repairs over the past decade. Photo by Dave Fornell
Blog | Structural Heart
Creating a Structural Heart Program is an Investment in the Future of the Hospital

As a medical technology journalist, a little more than a decade ago I found myself sitting in those late afternoon ...

Home April 21, 2021
Home
News
North American COVID-19 STEMI Research Reveals High Mortality and Atypical Symptoms

April 20, 2021 – The Minneapolis Heart Institute Foundation (MHIF) announced the first publication of outcomes from the ...

Home April 20, 2021
Home
The reSept ASD Occluder is the first structural heart occluder with a metal-free, bioresorbable frame. The novel implant is designed to overcome the limitations of current transcatheter occluders. It is hoped the design will reduce the risk of complications associated with the long-term presence of metal in the heart and to preserve future treatment options requiring transseptal intervention.
News | Structural Heart Occluders
Bioresorbable ASD Occluder Prepares to Enter U.S. Clinical Trial

April 20, 2021 — Start-up medical device company atHeart Medical announced it is initiating its U.S. investigational ...

Home April 20, 2021
Home
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and share to the vessel and movement.
News | Stents
First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized ...

Home April 14, 2021
Home
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now